|Security||RKDA / Arcadia Biosciences, Inc. (039014105)|
|President and CEO||Rey Eric J.|
|Institutional Shares||159,549 - 3.34%|
|Common Shares Outstanding||4,774,364 shares (as of 2018-06-30)|
|Institutional Value||$ 1,039,000 USD|
Institutional Stock Ownership and Shareholders
Arcadia Biosciences, Inc. (NASDAQ:RKDA) has 3 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 159,549 shares.
Largest shareholders include
Sabby Management, LLC, BlackRock Fund Advisors, and BlackRock Investment Management, LLC.
Arcadia Biosciences, Inc. (NASDAQ:RKDA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|Sabby Management, LLC||150,376||121,690||-19.08||3,611||1,004||-72.20|
|BlackRock Fund Advisors||34,783||35,655||2.51||68||33||-51.47|
|BlackRock Investment Management, LLC||2,204||2,204||0.00||4||2||-50.00|
Related News Stories
Good afternoon, and welcome to Arcadia Biosciences' Second Quarter 2018 Earnings Conference Call. Today's presenters will be Raj Ketkar, President and CEO; and Matthew Plavan, CFO. This call is being webcast, and you can refer to the company's press release and slides at arcadiabio.com. (1-0)
The following slide deck was published by Arcadia Biosciences in conjunction with their 2018 Q2 earnings call. (1-1)
I highlight a number of reasons why I've taken a speculative position in RKDA, including commercialization prospects and cash on hand relative to historical burn rates. (5-3)
Recent balance sheet improvements and a diverse pipeline of desirable plant traits for major crops mitigate the risk inherent in the micro-cap space. (12-4)
Good afternoon, and welcome to Arcadia Biosciences First Quarter 2018 Earnings Conference Call. Today’s presenters will be Raj Ketkar, President and CEO; and Matt Plavan, CFO. This call is being webcast, and you can refer to the company’s press release and slides at arcadiabio.com. (12-8)
as of ET